Business
Amarantus Announces Upcoming Investor Presentations
Amarantus Announces Upcoming Investor Presentations.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus Announces Upcoming Investor Presentations\n\n\n\n\n\nAmarantus Announces Upcoming Investor Presentations\nPR Newswire\nSAN FRANCISCO, May 27, 2016\n\n\n\nSAN FRANCISCO, May 27, 2016 /PRNewswire/ --\n\nAmarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & CEO Gerald E. Commissiong will be presenting at two upcoming investor conferences:\n\nSeeThru Equity MicroCap Conference \n\nWhere: Convene Conference Center, 730 Third Avenue, New York City, NY\n\nWhen: Tuesday, May 31st, 2016 at 3:00pm\n\nMarcum MicroCap Conference \n\nWhere: Grand Hyatt Hotel, 109 East 42nd St, New York, NY\n\nWhen: Wednesday, June 1st, 2016 at 3:00pm\n\nAbout Amarantus BioScience Holdings, Inc. \n\nAmarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS also owns 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. MANF was discovered from the Company's proprietary discovery engine PhenoGuard.\n\nFor further information please visit http://www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.\n\nForward-Looking Statements \n\nCertain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-...